[1]孟祥云,张之弘,汪永锋,等.当归多糖对糖尿病大鼠脂代谢及脂肪因子的影响?[J].西部中医药,2021,34(11):33-36.[doi:10.12174/j.issn.2096-9600.2021.11.07]
 MENG Xiangyun,ZHANG Zhihong,WANG Yongfeng,et al.Influence of Angelica Polysaccharide on Lipid Metabolism and Adipokine in Diabetic Rats[J].Western Journal of Traditional Chinese Medicine,2021,34(11):33-36.[doi:10.12174/j.issn.2096-9600.2021.11.07]
点击复制

当归多糖对糖尿病大鼠脂代谢及脂肪因子的影响?
分享到:

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
34
期数:
2021年11期
页码:
33-36
栏目:
药理研究
出版日期:
2021-11-15

文章信息/Info

Title:
Influence of Angelica Polysaccharide on Lipid Metabolism and Adipokine in Diabetic Rats
作者:
孟祥云12 张之弘3 汪永锋4 郭树明1 王晓怀12 杨丽霞2
1.甘肃省中医院,甘肃 兰州 730050
2.甘肃省中医药研究院
3.张掖市甘州区人民医院
4.甘肃中医药大学
Author(s):
MENG Xiangyun12 ZHANG Zhihong3 WANG Yongfeng4 GUO Shuming1 WANG Xiaohuai12 YANG Lixia2
1.Gansu Provincial Hospital of Traditional Chinese Medicine, Lanzhou 730050, China
2.Gansu Provincial Academy of Chinese Medicine
3.Zhangye City Ganzhou District People’s Hospital
4.Gansu University of Chinese Medicine
关键词:
糖尿病2型血脂脂肪细胞因子当归多糖大鼠
Keywords:
type 2 diabetes mellitusblood lipidadipokineAPrats
分类号:
R255.4
DOI:
10.12174/j.issn.2096-9600.2021.11.07
文献标志码:
A
摘要:
目的探讨当归多糖对糖尿病大鼠脂代谢及脂肪因子的影响。 方法将经链脲佐菌素(streptozotocin,STZ)诱导的2型糖尿病大鼠随机分为模型组、正常组、吡格列酮组及当归多糖低、中、高剂量组,每组10只。模型组、正常组给予生理盐水10 mL/kg灌胃,当归多糖各剂量组分别予400、200、100 mg/kg药物灌胃,吡格列酮组给予吡格列酮10 mg/kg灌胃。每日灌胃1次,灌胃4周后观察干预期间及干预后大鼠的一般情况及体质量变化情况,检测大鼠血脂[总胆固醇(total cholesterol,TC)、甘油三酯(triglyceride,TG)、低密度脂蛋白(low density lipoprotein,LDL)、高密度脂蛋白(high density lipoprotein,HDL)]、脂肪细胞因子[瘦素(leptin,LEP)、脂联素(adiponectin,ADPN)、抵抗素(RSTN)]以及脂肪细胞变化情况。 结果模型组大鼠毛色枯槁,活动量下降,二便增多。经当归多糖干预后各组大鼠与吡格列酮组活动量基本正常、毛色光泽,大小便较模型组好转,较正常组偶有增多。与正常组比较,模型组大鼠体质量增长速度较快;与模型组比较,各药物干预组大鼠体质量增长速度均较慢。药物干预各组均能降低血清TC、TG、LDL,LEP和RSTN含量,提高HDL及ADPN水平;其中当归多糖高剂量组、吡格列酮组与模型组比较差异显著(P<0.01)。当归多糖各剂量组随着给药剂量的增加,脂肪细胞大小均匀,排列逐渐致密整齐,细胞截面基本恢复正常,空泡及囊腔样病变明显减轻。 结论当归多糖能调节2型糖尿病大鼠脂代谢水平,增加血清脂肪因子ADPN含量,降低LEP、RSTN含量,且对脂肪组织有一定的修复和保护作用。
Abstract:
ObjectiveTo explore the effects of angelica polysaccharide (AP) on lipid metabolism and adipokine in diabetic rats. MethodsAll STZ-induced DM rats were randomized into the model group, the normal group, pioglitazone group, low, moderate and high dosages groups of AP, ten rats in each group. The model group and the normal group were drenched with physiological saline, 10mL/kg, different dosages groups of AP accepted intragastric administration of 400, 200 and 100mg/kg AP, and pioglitazone group was given with pioglitazone, 10mg/kg, once each day. After four weeks of intragastric administration, to observe general conditions and the changes of body mass during the intervention period and after the intervention, to detect blood lipid (TC, TG, LDL, HDL), adipocytokines (LEP, ADPN, RSTN) and the changes of fat cells of the rats. ResultsRat hair withered, the activity decreased, stool and urine increased in the model group. After intervention, compared with pioglitazone group, the activity was basically normal, the hair color was shiny in different dosages groups of AP, stool and urine were better than these in the model group, and increased occasionally compared with these of the blank group. Compared with the blank group, the body mass of rats increased rapidly in the model group; compared with the model group, the growth rate of body mass of the rats was slower in drug intervention groups. Different groups of drug intervention could lower the contents of TC, TG, LDL, LEP and RSTN, raise the levels of HDL and ADPN; among them, the difference was significant when high dosage group of AP and pioglitazone group were compared with the model group (P<0.01). As the medication dose increased in different dosages groups of AP, the size of adipocytes was uniform, the arrangement was gradually dense and neat, the cell cross section basically returned to normal, and the vacuole and cystic lesions were significantly reduced. ConclusionAP could regulate the level of lipid metabolism in type 2 diabetic rats, increase the content of serum adipokine ADPN, reduce the content of LEP and RSTN, and have certain repair and protection effect on adipose tissue.

相似文献/References:

[1]贾晓杰,刘志跃△.红花制剂在糖尿病及其并发症中的研究进展[J].西部中医药,2013,26(03):127.
 JIA Xiaojie,LIU Zhiyue.Research Progress of Safflower Preparation in Diabetes Mellitus and the Complication[J].Western Journal of Traditional Chinese Medicine,2013,26(11):127.
[2]范宗慧.温肾健脾法治疗糖尿病心得[J].西部中医药,2012,25(09):43.
 FAN Zong-hui.Experience on Method of WenShen JianPi in Treating Diabetes[J].Western Journal of Traditional Chinese Medicine,2012,25(11):43.
[3]张国民.消渴清颗粒治疗糖尿病周围神经病变疗效分析[J].西部中医药,2012,25(08):66.
 ZHANG Guo-min.XiaoKeQing Granules in Treating Diabetic Peripheral Neuropathy[J].Western Journal of Traditional Chinese Medicine,2012,25(11):66.
[4]张载宏.丹红注射液联合多贝斯治疗糖尿病周围神经病变临床疗效观察[J].西部中医药,2013,26(07):74.
 ZHANG Zaihong.Clinical Observation on DanHong Injection and Calcium Dobesilate Capsules in Treating Diabetic Peripheral Neuropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(11):74.
[5]段丽萍.中西医结合治疗糖尿病周围神经病变30例[J].西部中医药,2013,26(07):90.
 DUAN Liping.Integrative Medicine in Treating 30 Cases of Diabetic Peripheral Neuropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(11):90.
[6]龚云,王超,亢建国.运动结合灵芝多糖干预对糖尿病大鼠血脂的影响[J].西部中医药,2013,26(08):8.
 GONG Yun,WANG Chao,KANG Jianguo.Effects of Exercise and Ganoderan Intervention on Blood Fat of Rats with Diabetes Mellitus[J].Western Journal of Traditional Chinese Medicine,2013,26(11):8.
[7]呼宝娟.护理干预对肺结核合并糖尿病患者生活质量的影响[J].西部中医药,2013,26(09):125.
 HU Baojuan.Effects of Nursing Intervention on Life Quality of Diabetic Patients Complicated with Pulmonary Tuberculosis[J].Western Journal of Traditional Chinese Medicine,2013,26(11):125.
[8]张艳玲,高文菊.系统性干预对糖尿病并发症发生发展的影响[J].西部中医药,2013,26(12):81.
 ZHANG Yanling,GAO Wenju.Effects of Systematic Intervention on the Onset and Progression of Diabetic Complications[J].Western Journal of Traditional Chinese Medicine,2013,26(11):81.
[9]童玲利.外伤性跟骨骨折合并糖尿病患者围手术期护理体会[J].西部中医药,2014,27(02):131.
 TONG Lingli.Perioperative Care for the Patients with Diabetes Mellitus and Traumatic Calcaneal Fracture[J].Western Journal of Traditional Chinese Medicine,2014,27(11):131.
[10]陈海燕,刘怀珍.糖尿病周围神经病变的中医研究[J].西部中医药,2014,27(03):138.
 CHEN Haiyan,LIU Huaizhen.TCM Study of Diabetic Peripheral Neuropathy[J].Western Journal of Traditional Chinese Medicine,2014,27(11):138.
[11]段尚勤.糖脂消合罗格列酮治疗2型糖尿病合并非酒精性脂肪肝疗效观察[J].西部中医药,2013,26(02):88.
 DUAN Shangqin.Clinical Observation on TangZhiXiao and Rosiglitazone Maleate in Treating Type 2 Diabetes Mellitus Complicated with Non Alcoholic Fatty Liver Disease[J].Western Journal of Traditional Chinese Medicine,2013,26(11):88.
[12]张军和,杨振亚,张永琴.安糖1号治疗初发2型糖尿病并代谢综合征40例临床观察[J].西部中医药,2013,26(05):1.
 ZHANGJunhe,YANGZhenya,ZHANGYongqin.ClinicalObservationonAnTangNo.1intheTreatmentfor40CasesofDiabetesMellitusTypeTwoatPrimaryStageComplicatedwithMetabolismSyndrome[J].Western Journal of Traditional Chinese Medicine,2013,26(11):1.
[13]吕志芹,魏文慧.胰岛素联合痰热清治疗2型糖尿病合并肺部感染49例[J].西部中医药,2013,26(06):85.
 LV Zhiqin,WEI Wenhui.Insulin and TanReQing Injection in Treating 49 Cases of Diabetes Mellitus Type Two Complicated with Pulmonary Infection[J].Western Journal of Traditional Chinese Medicine,2013,26(11):85.
[14]刘希宏.中西药物联用对老年高血压合并2型糖尿病患者肾功能的保护作用[J].西部中医药,2012,25(07):9.
 LIU Xi-hong.Protection of Integrated Traditional Chinese and Western Medicine on Renal Function of Patients with Senile Hypertension and Type 2 Diabetes Mellitus[J].Western Journal of Traditional Chinese Medicine,2012,25(11):9.
[15]梁伟.护理干预在2型糖尿病患者护理中的应用[J].西部中医药,2013,26(12):128.
 LIANG Wei.Application of Nursing Intervention to the Patients with Diabetes Mellitus Type 2[J].Western Journal of Traditional Chinese Medicine,2013,26(11):128.
[16]王璟.中药对胰岛素治疗2型糖尿病低血糖发生率的影响[J].西部中医药,2014,27(04):94.
 WANG Jing.Effects of Herbs on the Incidence Rate of Hypoglycemia of the Patients with Type Two Diabetes Mellitus[J].Western Journal of Traditional Chinese Medicine,2014,27(11):94.
[17]齐丽丽,侯敏,尚新秀,等.2 型糖尿病患者八段锦锻炼态度的调查*[J].西部中医药,2014,27(08):36.
[18]张智明,陈孝民△.芪蛭消渴方联合西药基础治疗对 2 型糖尿病症状及血脂的影响*[J].西部中医药,2014,27(08):79.
[19]马红,王海红Δ,蒲小庆,等.中西医结合治疗 2 型糖尿病 68 例[J].西部中医药,2014,27(08):95.
[20]夏海萍,黄琴清,李志英,等.循证护理应用于2型糖尿病合并高血压病患者中的效果观察[J].西部中医药,2014,27(10):140.

备注/Memo

备注/Memo:
孟祥云(1983—),女,硕士学位,主管检验师。研究方向:中药分子生物学研究。国家自然科学基金(81560764);甘肃省中医药管理局科研项目(GZK-2016-48、GZK-2017-4);甘肃省中医院院级课题(院2017-10);兰州市科技发展指导性项目(2020-ZD-34)。
更新日期/Last Update: 2022-08-09